A phase II neoadjuvant trial of concurrent trastuzumab and paclitaxel without anthracycline in women with HER2-positive operable breast cancer

被引：0
|
作者：
Jinno, H. [1 ]
Sato, T. [1 ]
Takahashi, M. [1 ]
Hayashida, T. [1 ]
Sakata, M. [1 ]
Hirose, S. [1 ]
Kitagawa, Y. [1 ]
机构：
[1] Keio Univ, Sch Med, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e11070
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11070
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Neoadjuvant trial of bevacizumab (B) and trastuzumab (T) in combination with weekly paclitaxel (P) as neoadjuvant treatment in HER2-positive breast cancer: A phase II trial (AVANTHER). Analysis of biomarkers
    Fernandez, M.
    Martinez, N.
    Calvo, I.
    Garcia, E.
    Ugidos, L.
    Herrero, M.
    Quijano, Y.
    Duran, H.
    Garcia, M.
    Suarez, A.
    Lopez-Rios, F.
    Perez, D.
    Perea, S.
    Hidalgo, M.
    Garcia-Estevez, L.
    CANCER RESEARCH, 2013, 73
  • [22] Final results of neoadjuvant trial of bevacizumab (B) and trastuzumab (T) in combination with weekly paclitaxel (P) as neoadjuvant treatment in HER2-positive breast cancer: A phase II trial (AVANTHER)
    Fernandez, M.
    Calvo, I.
    Martinez, N.
    Herrero, M.
    Quijano, Y.
    Duran, H.
    Garcia-Aranda, M.
    Suarez, A.
    -Rios, F. Lopez
    Perez, D.
    Perea, S.
    Hidalgo, M.
    Garcia-Estevez, L.
    CANCER RESEARCH, 2012, 72
  • [23] A Phase II Trial of Oxaliplatin and Trastuzumab in the Treatment of HER2-Positive Metastatic Breast Cancer
    Yardley, Denise A.
    Daniel, Davey
    Stipanov, Michael
    Drosick, D. Randolph
    Mainwaring, Mark
    Peyton, James
    Shastry, Mythili
    Hainsworth, John D.
    CANCER INVESTIGATION, 2010, 28 (08) : 865 - 871
  • [24] Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer.
    Carey, Lisa A.
    Berry, Donald A.
    Ollila, David
    Harris, Lyndsay
    Krop, Ian E.
    Weckstein, Douglas
    Henry, Norah Lynn
    Anders, Carey K.
    Cirrincione, Constance
    Winer, Eric P.
    Perou, Charles M.
    Hudis, Clifford
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [25] Should trastuzumab be administered concomitantly with anthracycline in women with early, HER2-positive breast cancer?
    Montemurro, Filippo
    TRANSLATIONAL CANCER RESEARCH, 2014, 3 (06) : 541 - 546
  • [26] Neoadjuvant bevacizumab (B) and trastuzumab (T) in combination with weekly paclitaxel (P) as neoadjuvant treatment in HER2-positive breast cancer: Results from a phase II trial (AVANTHER)
    Fernandez Abad, Maria
    Calvo, Isabel
    Martinez, Noelia
    Herrero, Mercedes
    Quijano, Yolanda
    Duran, Hipolito
    Garcia Aranda, Mariola
    Suarez, Ana
    Lopez-Rios, Fernando
    Perez, Diego
    Perea, Sofia
    Hidalgo, Manuel
    Garca-Estevez, Laura
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] Phase II neoadjuvant trial of albumin-bound paclitaxel, trastuzumab and pertuzumab followed by anthracycline based regimens in patients with operable HER2 positive breast cancer (OMC-BC05).
    Iwamoto, Mitsuhiko
    Ikari, Ayana
    Tominaga, Tomo
    Maezawa, Saki
    Sakane, Junna
    Oku, Hiroyo
    Yoshidome, Katsuhide
    Morimoto, Takashi
    Fujioka, Hiroya
    Hagihara, Seita
    Nitta, Toshikatsu
    Matsutani, Ayumi
    Kimura, Kosei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [28] Phase II neoadjuvant trial of Albumin-Bound Paclitaxel, Trastuzumab and Pertuzumab followed by anthracycline based regimens in patients with operable Her2 positive breast cancer (OMC-BC05)
    Iwamoto, M.
    Matsutani, A.
    Ikari, A.
    Tominaga, T.
    Maezawa, S.
    Oku, H.
    Kimura, K.
    BREAST, 2021, 56 : S52 - S52
  • [29] Paclitaxel, carboplatin, and trastuzumab in HER2-positive metastatic breast cancer
    Andrew D. Seidman
    Larry Norton
    Current Oncology Reports, 2005, 7 (1) : 9 - 11
  • [30] A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
    Patel, Tejal A.
    Ensor, Joe E.
    Creamer, Sarah L.
    Boone, Toniva
    Rodriguez, Angel A.
    Niravath, Poly A.
    Darcourt, Jorge G.
    Meisel, Jane L.
    Li, Xiaoxian
    Zhao, Jing
    Kuhn, John G.
    Rosato, Roberto R.
    Qian, Wei
    Belcheva, Anna
    Schwartz, Mary R.
    Kaklamani, Virginia G.
    Chang, Jenny C.
    BREAST CANCER RESEARCH, 2019, 21 (01)
12345